000908208 001__ 908208
000908208 005__ 20220621190117.0
000908208 0247_ $$2doi$$a10.1093/neuonc/noy148.801
000908208 0247_ $$2ISSN$$a1522-8517
000908208 0247_ $$2ISSN$$a1523-5866
000908208 037__ $$aFZJ-2022-02459
000908208 082__ $$a610
000908208 1001_ $$0P:(DE-HGF)0$$aCeccon, Garry$$b0$$eCorresponding author
000908208 245__ $$aNIMG-79. EARLY TREATMENT RESPONSE ASSESSMENT USING O-(2-18F-FLUOROETHYL)-L-TYROSINE (FET) PET COMPARED TO MRI IN MALIGNANT GLIOMAS TREATED WITH ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY
000908208 260__ $$c2018
000908208 3367_ $$2DataCite$$aText
000908208 3367_ $$0PUB:(DE-HGF)4$$2PUB:(DE-HGF)$$aCommunication$$bcomm$$mcomm$$s1655805436_1548
000908208 3367_ $$2BibTeX$$aMISC
000908208 3367_ $$2ORCID$$aOTHER
000908208 3367_ $$2DINI$$aOther
000908208 3367_ $$04$$2EndNote$$aPersonal Communication
000908208 520__ $$aAbstractBACKGROUNDThe goal of this prospective study was to compare the value of conventional MRI and O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET for response assessment in patients with malignant glioma treated with first-line adjuvant temozolomide chemotherapy (TMZ).METHODSAfter biopsy/resection and completion of radiotherapy with concomitant temozolomide, 34 malignant glioma patients (glioblastoma, n=31; IDH-wildtype anaplastic astrocytoma, n=2; H3K27-mutated midline glioma, n=1) (age range, 20–66 years) were subsequently treated with adjuvant TMZ (5/28). FET-PET scans were performed at baseline and after 10–12 weeks. The first follow-up MRI after radiotherapy (9 ± 3 weeks) was compared with the early postoperative MRI. We obtained FET metabolic tumor volumes (MTV) and tumor/brain ratios (TBR). Threshold values of FET-PET parameters for treatment response were established by ROC analyses using the progression-free survival (PFS) ≤/>9 months as reference. MRI response assessment was based on RANO criteria. The predictive ability of FET-PET thresholds and MRI changes on early response assessment was evaluated subsequently concerning PFS using univariate survival estimates.RESULTSRelative TBR changes were not predictive for a PFS>9 months (P>0.05), whereas the absolute MTV at follow-up significantly predicted a PFS>9 months (P=0.016; threshold, 14.5 ml). The relative MTV change enabled the most significant PFS prediction. Responders defined by relative MTV changes (threshold, ≤0%) had a significantly 2-fold longer PFS than non-responders (16 vs. 8 months, P=0.003). RANO criteria at the first follow-up MRI after radiotherapy were not predictive for a PFS>9 months (P=0.260). CONCLUSIONS: FET-PET appears to be useful for identifying responders to adjuvant TMZ early after treatment initiation.
000908208 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000908208 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000908208 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b1$$ufzj
000908208 7001_ $$aTscherpel, Caroline$$b2
000908208 7001_ $$0P:(DE-Juel1)156211$$aDunkl, Veronika$$b3
000908208 7001_ $$0P:(DE-HGF)0$$aRapp, Marion$$b4
000908208 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b5$$ufzj
000908208 7001_ $$0P:(DE-HGF)0$$aHerrlinger, Ulrich$$b6
000908208 7001_ $$0P:(DE-HGF)0$$aRosen, Jurij$$b7
000908208 7001_ $$0P:(DE-Juel1)190394$$aWollring, Michael$$b8$$ufzj
000908208 7001_ $$0P:(DE-Juel1)131794$$aShah, Nadim J$$b9$$ufzj
000908208 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R$$b10$$ufzj
000908208 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b11$$ufzj
000908208 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b12$$ufzj
000908208 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noy148.801$$gVol. 20, no. suppl_6, p. vi193 - vi193$$x1523-5866$$y2018
000908208 909CO $$ooai:juser.fz-juelich.de:908208$$pVDB
000908208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b1$$kFZJ
000908208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b5$$kFZJ
000908208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)190394$$aForschungszentrum Jülich$$b8$$kFZJ
000908208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b9$$kFZJ
000908208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b10$$kFZJ
000908208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b11$$kFZJ
000908208 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b12$$kFZJ
000908208 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000908208 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-03$$wger
000908208 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2019$$d2021-02-03
000908208 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bNEURO-ONCOLOGY : 2019$$d2021-02-03
000908208 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000908208 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x1
000908208 9201_ $$0I:(DE-Juel1)VDB1046$$kJARA-BRAIN$$lJülich-Aachen Research Alliance - Translational Brain Medicine$$x2
000908208 980__ $$acomm
000908208 980__ $$aVDB
000908208 980__ $$aI:(DE-Juel1)INM-4-20090406
000908208 980__ $$aI:(DE-Juel1)INM-11-20170113
000908208 980__ $$aI:(DE-Juel1)VDB1046
000908208 980__ $$aUNRESTRICTED